ArticleMicrobiology spectrum2022
Changing Patterns of SARS-CoV-2 Seroprevalence among Canadian Blood Donors during the Vaccine Era.
Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- Blood donor hepatitis B data: An under-recognized surveillance resource in Canada.Canadian liver journal · 2026Article
- The impact of statistical adjustment for assay performance on inferences from SARS-CoV-2 serological surveillance studies.American journal of epidemiology · 2025Article
- Seroepidemiology of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Blood Donors from Western Romania, August-September 2023.Microorganisms · 2025Article
- Influenza and COVID-19 vaccination in Canadian blood donors: A comparison across pre- and post-pandemic periods.Vox sanguinis · 2025Article
- Comparison of six COVID-19 serology assays for detection of antibodies from patients infected with ancestral and a spectrum of SARS-CoV-2 variants.Access microbiology · 2025Article
- SARS-CoV-2 vaccination in Canadian blood donors: Insight into donor representativeness of the general population.Vaccine: X · 2024Article
- Temporal trends in disparities in COVID-19 seropositivity among Canadian blood donors.International journal of epidemiology · 2024Article
- SARS-CoV-2 seroprevalence in Nova Scotia blood donors.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2024Article
- Realistic Estimation of COVID-19 Infection by Seroprevalence Surveillance of SARS-CoV-2 Antibodies: An Experience From Korea Metropolitan Area From January to May 2022.Journal of Korean medical science · 2024Article
- Evaluation of Ortho VITROS and Roche Elecsys S and NC Immunoassays for SARS-CoV-2 Serosurveillance Applications.Microbiology spectrum · 2023Article
- The evolution of SARS-CoV-2 seroprevalence in Canada: a time-series study, 2020-2023.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2023Article
- Article
- Cross-Canada Variability in Blood Donor SARS-CoV-2 Seroprevalence by Social Determinants of Health.Microbiology spectrum · 2023Article
- An expanded role for blood donor emerging pathogens surveillance.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2023Article
- Article
- Lessons Learned from the COVID-19 Pandemic and How Blood Operators Can Prepare for the Next Pandemic.Viruses · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We monitored the seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid (anti-N; proxy of natural infection) and spike protein (anti-S; proxy for humoral immunity) antibodies in blood donors across Canada from January to November 2021. The first and second doses of vaccine were deployed over this time. Anti-N seroprevalence remained low overall (about 5% or lower) from January to November but was higher in racialized groups, younger age groups, and those living in materially deprived neighborhoods. Anti-S seroprevalence corresponded with the roll out of vaccines across the country, increasing in April in older donors and then progressively to younger age groups consistent with vaccination policies targeting oldest to youngest. By November, close to 100% of blood donors were positive for anti-S. Anti-S concentrations peaked by July and began waning by September to November particularly in older donors. These data have informed national and provincial public health policy in Canada throughout vaccination rollout.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.